(Q38182683)

30 August 2017

title

Current strategies for treatment of relapsed/refractory multiple myeloma (English)

1 reference

30 August 2017

5

Sagar Lonial

1 reference

30 August 2017

6

Paul G Richardson

1 reference

30 August 2017

4

Andrzej Jakubowiak

1 reference

30 August 2017

Jacob P Laubach

1

1 reference

30 August 2017

Peter M Voorhees

series ordinal

2

1 reference

30 August 2017

Hani Hassoun

series ordinal

3

1 reference

30 August 2017

publication date

29 January 2014

1 reference

Expert Review of Hematology

30 August 2017

published in

1 reference

30 August 2017

volume

7

1 reference

30 August 2017

issue

1

1 reference

30 August 2017

page(s)

97-111

1 reference

Improved survival in multiple myeloma and the impact of novel therapies

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Lenalidomide after stem-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

International uniform response criteria for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Molecular pathogenesis and a consequent classification of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

The molecular classification of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Clonal competition with alternating dominance in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Exome sequencing in tracking clonal evolution in multiple myeloma following therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Pomalidomide therapy for myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 R

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Second auto-SCT for treatment of relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Transplantation as salvage therapy for high-risk patients with myeloma in relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Salvage second hematopoietic cell transplantation in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Management of treatment-emergent peripheral neuropathy in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du M

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2014.882764

10.1586/17474086.2014.882764

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference